| 注册
首页|期刊导航|中国临床药理学杂志|沙美特罗替卡松联合噻托溴铵治疗稳定期老年COPD患者的临床研究

沙美特罗替卡松联合噻托溴铵治疗稳定期老年COPD患者的临床研究

周霞 娄丽丽 杨柳 程慧鑫

中国临床药理学杂志2024,Vol.40Issue(17):2459-2463,5.
中国临床药理学杂志2024,Vol.40Issue(17):2459-2463,5.DOI:10.13699/j.cnki.1001-6821.2024.17.001

沙美特罗替卡松联合噻托溴铵治疗稳定期老年COPD患者的临床研究

Clinical trial of salmeterol and fluticasone propionate combined with tiotropium in treatment of elderly patients with stable COPD

周霞 1娄丽丽 1杨柳 1程慧鑫1

作者信息

  • 1. 大庆龙南医院老年病科,黑龙江大庆 163000
  • 折叠

摘要

Abstract

Objective To analyze the efficacy of salmeterol rotticasone combined with tiotropium bromide in the treatment of elderly patients with stable chronic obstructive pulmonary disease(COPD)and its influence on serum procalcitonin(PCT),serum amyloid A(SAA)and albumin-to-fibrinogen ratio(AFR)levels.Methods The elderly patients with stable COPD were divided into control group and treatment group.The control group was treated with salmeterol rotticasone inhalation powder(1 inhalation each time,twice a day),while the treatment group was given tiotropium bromide inhaled powder aerosol treatment(1 inhalation each time once a day)on the basis of the control group.Patients in two groups were treated for 3 months.The clinical efficacy and differences in pulmonary function[forced expiratory volume in one second(FEV1),FEV1/forced vital capacity(FEV1/FVC),peak expiratory flow(PEF)],modified British Medical Research Council respiratory questionnaire(mMRC)score,COPD Assessment Test(CAT)score and serum PCT,SAA and AFR levels were compared;and the safety was evaluated.Results Fifty-two patients and fifty-eight patients were included in treatment group and control group,respectively.After treatment,the total effective rates in treatment group and control group were 90.38%(47 cases/52 cases)and 75.86%(44 cases/58 cases)(P<0.05).The FEV1 values in treatment group and control group were(1.49±0.33)and(1.36±0.29)L;the FEV1/FVC values were(61.28±10.56)%and(57.41±10.03)%;PEF values were(5.32±0.88)and(4.93±0.75)L·s-1;mMRC scores were(0.99±0.24)and(1.21±0.27)points;the CAT scores were(11.58±3.02)and(14.26±3.71)points;PCT levels were(0.76±0.11)and(0.85±0.18)µg·L-1;SAA levels were(34.59±4.15)and(37.66±5.34)mg·L-1;AFR levels were 5.97±1.12 and 5.53±1.06,respectively.Compared with the control group,the above indexes in the treatment group were statistically significant(all P<0.05).The main adverse drug reactions in treatment group were dry mouth,constipation and dizziness and nausea,and the main adverse drug reactions in control group were dry mouth,constipation,and dizziness and nausea.The total incidence rates of adverse drug reactions in treatment group and control group were 21.15%(11 cases/52 cases)and 13.79%(8 cases/58 cases)respectively,with no statistical significance(P>0.05).Conclusion Salmeterol ticasone inhalation powder and tiotropium bromide inhaled powder aerosol can effectively enhance the clinical efficacy of elderly patients with stable COPD,improve the pulmonary function,relieve the body's inflammation,and promote the improvement of disease condition,with good safety.

关键词

沙美特罗替卡松吸入粉雾剂/噻托溴铵吸入粉雾剂/慢性阻塞性肺疾病/稳定期/老年/疗效/炎症反应

Key words

salmeterol rotticasone inhalation powder/tiotropium bromide inhaled powder aerosol/chronic obstructive pulmonary disease/stable period/old age/curative effect/inflammatory response

分类

医药卫生

引用本文复制引用

周霞,娄丽丽,杨柳,程慧鑫..沙美特罗替卡松联合噻托溴铵治疗稳定期老年COPD患者的临床研究[J].中国临床药理学杂志,2024,40(17):2459-2463,5.

中国临床药理学杂志

OA北大核心CSTPCD

1001-6821

访问量0
|
下载量0
段落导航相关论文